Show
Sort by
-
SOX11 is a lineage-survival oncogene in neuroblastoma
-
Targeted analysis of TP53 pathway SNPs in neuroblastoma patients
-
Time-resolved transcriptome analysis of TH-MYCN driven hyperplastic ganglia and tumors marks BRD3 as a novel candidate oncogene
-
Genome-wide methylation analysis unravels differential DNA methylation patterns between (prognostic) neuroblastoma patient subgroups
-
The MYCN/miR-26a-5p/LIN28B regulatory axis controls MYCN-driven LIN28B upregulation in neuroblastoma
-
Promoter DNA-methylation in the TH-MYCN neuroblastoma mouse model
-
MYCN safeguards its upregulated expression through negatively controlling its upstream miRNAs
-
Reduced DICER1 functionality in neuroblastoma through reduced expression levels or somatic mutations
-
The HBP1 tumor suppressor is a druggable ALK downregulated gene controlling MYCN activity
-
Evaluation of targeted drugs in combination with the MDM2 antagonist RG7388 in neuroblastoma